Definium advances LSD-assisted therapy for depression with a public company update on strategy, clinical direction, and its wider psychedelic medicine ambitions

Definium centers LSD-assisted therapy for depression in a corporate update that positions the company within the emerging psychedelic medicine sector. The focus is on turning LSD into a regulated mental health treatment and communicating progress, direction, and investor-facing milestones. Depression sits at the core of the therapeutic target, with LSD presented as a candidate for clinically supervised treatment rather than recreational use. The update signals how biotech and public market actors are trying to build drug development pathways, regulatory credibility, and commercial narratives around psychedelic-assisted care. The broader significance lies in the continued shift of psychedelics into mainstream health and industry frameworks. Corporate announcements like this help map where capital, clinical development, and treatment expectations are converging around LSD as a potential psychiatric intervention.